What is the chemical structure of mivamutide injection? What are the characteristics

Mifamurtide injection(Mifamurtide) is a synthetic lipopeptide immunomodulator, mainly used for the treatment of osteosarcoma. The chemical structure of mivamuttide is based on the granulocyte-macrophage stimulator Muramyl dipeptide (MDP), which enhances its biological activity and targeting by combining with liposomes to form a liposome-encapsulated structure. Specifically, the chemical composition of mivamut is a Muramyl dipeptide molecule combined with 20-carbon fatty acid (phosphatidylethanolamine) through liposome technology to form nano-scale liposome particles.

This liposome carrier system allows mivamut peptide to be more effectively taken up by mononuclear-macrophages, activate the body's immune response, and promote the recognition and clearance of tumor cells. Compared with traditional immunomodulators, the liposome structure of miavastatin significantly extends the half-life in the body, reduces drug degradation, improves targeted delivery efficiency, and reduces non-specific toxic and side effects.

In addition, Muramyl dipeptide in the miramyl peptide molecule is a natural component of the bacterial cell wall. As an innate immune activator, it triggers downstream immune signaling pathways and enhances anti-tumor immune effects by activating NOD2 receptors. This molecular design combines the natural recognition mechanism of the immune system with modern nano-drug carrier technology, making mivamutide an effective and safe immune auxiliary treatment.

Overall, the chemical structure of mivamutin injection is centered on liposome-encapsulatedMuramyl dipeptide, which embodies the modern drug design concept and has both targeting and immune activation functions, providing a solid pharmacological basis for the adjuvant treatment of osteosarcoma.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/mepact